Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Navicare Biotech Co's FCF Margin % or its related term are showing as below:
ROCO:8472'
s FCF Margin % Range Over the Past 10 Years
Min: -143.15 Med: -12.46 Max: 22.23
Current: -0.69
During the past 13 years, the highest FCF Margin % of Navicare Biotech Co was 22.23%. The lowest was -143.15%. And the median was -12.46%.
ROCO:8472's FCF Margin % is ranked worse than 70.98% of 1127
companies
in the Retail - Cyclical industry
Industry Median: 3.06
vs ROCO:8472: -0.69
Navicare Biotech Co FCF Margin % Related Terms
Navicare Biotech Co FCF Margin % Historical Data
* Premium members only.
The historical data trend for Navicare Biotech Co's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:8472 vs AMZN, BABA, PDD: FCF Margin % Comparison
For the Internet Retail subindustry, Navicare Biotech Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Navicare Biotech Co FCF Margin % vs Retail - Cyclical Industry
For the Retail - Cyclical industry and Consumer Cyclical sector, Navicare Biotech Co's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Navicare Biotech Co's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Navicare Biotech Co (ROCO:8472) has a FCF Margin % of 57.67% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Navicare Biotech Co and its competitors. According to the industry distribution chart, Navicare Biotech Co ranks #800 out of 1127 companies in the Retail - Cyclical industry, placing it in the top 71%.
Is Navicare Biotech Co's FCF Margin % too high?
Navicare Biotech Co's current FCF Margin % is 57.67%. The Retail - Cyclical industry median FCF Margin % is 3.06. Navicare Biotech Co's value of 57.67% is 1784.6% above this industry median. Based on the distribution chart, Navicare Biotech Co ranks #800 out of 1127 companies in the Retail - Cyclical industry, which is below the industry midpoint. Overall, Navicare Biotech Co has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Navicare Biotech Co's FCF Margin % compare to AMZN and BABA?
According to the Retail - Cyclical industry distribution chart, Navicare Biotech Co ranks #800 out of 1127 companies for FCF Margin %. This places Navicare Biotech Co in the lower half of its industry. The industry median FCF Margin % is 3.06. Navicare Biotech Co's value of 57.67% is 1784.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Retail - Cyclical company?
The median FCF Margin % among Retail - Cyclical companies is 3.06, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Navicare Biotech Co's current FCF Margin % of 57.67% is 1784.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Navicare Biotech Co and its competitors. For the Retail - Cyclical industry, the median FCF Margin % is 3.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Navicare Biotech Co's current FCF Margin % is 57.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Navicare Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Navicare Biotech Co (ROCO:8472) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$44.21, compared to a current price of NT$79.00 — trading 78.7% above its estimated fair value. The current FCF Margin % is 57.67% and 1784.6% above the Retail - Cyclical industry median of 3.06. Navicare Biotech Co's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Navicare Biotech Co (ROCO:8472), the current FCF Margin % is 57.67% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Navicare Biotech Co (ROCO:8472) Overvalued in 2026?
Based on GuruFocus' analysis, Navicare Biotech Co stock appears to be overvalued.
The current stock price of NT$79.00 is trading 78.7% above its estimated GF Value™ of NT$44.21.
GuruFocus considers Navicare Biotech Co to be Significantly Overvalued.
Key valuation signals for ROCO:8472:
FCF Margin %: 57.67%
GF Value™: NT$44.21 vs. price of NT$79.00 (78.7% above fair value)
Industry Position: 1784.6% above the Retail - Cyclical median (#800 of 1127)
No single metric tells the full story. See the ROCO:8472 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:8472 has been successfully added to your 
